A clinical efficacy and safety study of Insulin Glargine U300 in Chinese adult patients with uncontrolled Type 2 Diabetes Mellitus with a 3-month extension period

Trial Identifier: LPS16585
Sponsor: Sanofi
Start Date: May 2021
Primary Completion Date: February 2023
Study Completion Date: February 2023
Condition: Diabetes: Type 2

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language Description

Trial Locations

Country Location
China China, China